🟢 90/100

This product looks safe

  • Contains proprietary blend — exact ingredient amounts not disclosed
  • 67% of ingredients have research evidence
A Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Safety Alerts

ℹ️ Contains proprietary blend — exact ingredient amounts not disclosed

Label Data

1 Tablet(s) Serving Size
90 Servings
Other Combinations Product Type
67% Evidence Coverage

Supplement Facts — Evidence Check

10 mg (63% DV)
✅ Within RDA (0.7× RDA of 14 mg) 📚 193 studies (Tier A: 5, B: 63)
RDA 14mg This product: 10mg UL 35mg
50 mg (2941% DV)
📊 38.5× RDA — above typical dose (UL: 100 mg) 📚 113 studies (Tier A: 3, B: 35)
RDA 1.3mg This product: 50mg UL 100mg
Proprietary Blend
250 mg

Other Ingredients

Pyridoxine Hydrochloride Honey Niacinamide Calcium Stearate Arabic Gum

Label Claims — Verification

All Other
All Other (97% of products) Structure/Function (86% of products) Nutrient (36% of products)

Target Groups

Adult (18 - 50 Years) Gluten Free

Product Information

📋 Directions for Use

Suggested use: One tablet per day, or as directed.

⚠️ Warnings & Precautions

Caution: This product is processed in a facility that manufactures other products containing soy, milk, egg, wheat, peanut, tree nuts, fish, and shellfish.

🧪 Formulation Notes

Gluten free

Additional Information

Whole food supplements since 1929

Product Details

UPC / SKU 8 12122 01017 7
DSLD Entry Date 2021-11-19
Product Type Other Combinations
Form Tablet or Pill
DSLD ID 256280
Data Updated 2026-04-11

Research Evidence

241 Research Sources
55 Avg Quality Score
113 Meta Analysis
75 Systematic Review
32 Rct
11 Clinical Trial
3 Other
3 Regulatory Source
1 Cochrane Review
1 Narrative Review
1 Openfda Safety
A Niacin for primary and secondary prevention of cardiovascular events
Meta Analysis The Cochrane database of systematic reviews 2017
A Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases
Meta Analysis BMJ (Clinical research ed.) 2013
A Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients
Meta Analysis BMJ (Clinical research ed.) 2014
A A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk
Meta Analysis Nature medicine 2024
A Meta-analysis and imputation refines the association of 15q25 with smoking quantity
Meta Analysis Nature genetics 2010
A Genome-wide meta-analyses identify multiple loci associated with smoking behavior
Meta Analysis Nature genetics 2010
A Antidepressants for smoking cessation
Meta Analysis The Cochrane database of systematic reviews 2014
A Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne
Meta Analysis The Cochrane database of systematic reviews 2020
B Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis
Meta Analysis JAMA network open 2019
B Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis
Meta Analysis JAMA 2016
View all evidence for Niacin →

Compare Similar Products

View all Niacin products →